Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2–Targeted Therapies

22 Jul 2016

Abstract excerpt

Resistance limits the effectiveness of receptor tyrosine kinase (RTK)-targeted therapies. Combination therapies targeting resistance mechanisms can considerably improve response, but will require an improved understanding of when particular combinations will be effective. One common form of resistance is bypass signaling, wherein RTKs not targeted by an inhibitor can direct reactivation of pathways essential for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Treatment and Pharmacology
Share to HER2/EGFR in Cancer Research
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27450453
DOI: 10.1158/0008-5472.can-16-0123

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2–Targeted TherapiesPMID 27450453Read ↗

Durability of Kinase-Directed Therapies—A Network Perspective on Response and ResistanceSemantic proximity Read ↗

Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors.Semantic proximity Read ↗

Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast CancerSemantic proximity Read ↗

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.Semantic proximity Read ↗

Mapping the Pathways of Resistance to Targeted TherapiesSemantic proximity Read ↗

Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

The hallmarks of oncogenic signaling: From pathways to resistance in cancer therapy.Semantic proximity Read ↗

Dissecting signaling regulators driving AXL-mediated bypass resistance and associated phenotypes by phosphosite perturbationsSemantic proximity Read ↗

TAM Receptor Tyrosine Kinases in Cancer Drug ResistanceSemantic proximity Read ↗

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in CancerSemantic proximity Read ↗

Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung CancerSemantic proximity Read ↗

Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.